This first of it’s kind trial compares two leading DCB technologies.
Boston Scientific’s drug-coated balloon goes up against Medtronic’s DCB in first-of-its-kind trial
Top-line results from a head-to-head trial comparing Boston Scientific‘s (NYSE:BSX) Ranger drug-coated balloon and Medtronic‘s (NYSE:MDT) In.Pact Admiral DCB found no statistically significant difference in patency rates between the two drug-device products.
The trial is the first of its kind, according to Boston Scientific’s president of peripheral interventions, Jeff Mirviss.
“As a leader in the peripheral space, we wanted to deliver the type of evidence that could help physicians and hospital systems utilize more evidence-based medicine in the field. We wanted to do the type of trial that could advance the field forward,” Mirviss told Drug Delivery Business News.
